Palatin Technologies Inc. Shares Close the Day 18.3% Higher - Daily Wrap
The company saw its shares close the day 18.3% higher than yesterday, with trading volume higher than its 30 day average.
Sep 16, 2022 by Kwhen Finance Editors
Palatin Technologies Inc. (PTN) shares closed today 18.3% higher than it did at the end of yesterday. The stock is currently down 37.8% year-to-date, down 30.2% over the past 12 months, and down 51.0% over the past five years. Today, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 0.8%.
Trading Activity
- Shares traded as high as $8.16 and as low as $6.35 this week.
- Shares closed 66.8% below its 52-week high and 99.0% above its 52-week low.
- Trading volume this week was 81.5% lower than the 10-day average and 74.8% lower than the 30-day average.
- Beta, a measure of the stock’s volatility relative to the overall market stands at 1.5.
Technical Indicators
- The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.
- MACD, a trend-following momentum indicator, indicates an upward trend.
- The stock closed below its Bollinger band, indicating it may be oversold.
- The stock closed at 8.6% higher than its 5-day moving average, 35.9% higher than its 20-day moving average, and 9.6% higher than its 90-day moving average.
Fundamentals & Catalysts
- Over the past 12 months the company generated $-27,870,489 in earnings before interest and taxes from $-163,971 in revenue. It currently holds $72 million in cash and $7 million in debt.
- Its forward price-to-earnings (P/E) ratio of 0 is higher than its current P/E ratio of -49.36, implying that analysts are expecting a decrease in earnings.
- The company's price/earnings-to-growth ratio (PEG Ratio), a widely used indicator of a stock's true value while also factoring in expected earnings growth, currently stands at 0.03. A fairly valued company should have a PEG ratio of 1.0. When a company's PEG exceeds 1.0, it's considered overvalued while a stock with a PEG of less than 1.0 is considered undervalued.
- The company's debt-to-equity ratio, which measures the extent to which it finances its operations through debt, currently stands at 1.28 which means it currently has $1.28 of debt for every $1 of equity. Generally speaking, a debt to equity ratio below 1.0 is seen as relatively safe, while ratios of 2.0 or higher would be considered risky. Some industries are known for having much higher debt to equity ratios than others.
- The company's price-to-book ratio, which measures the market's valuation of a company relative to its book value, currently stands at 1.86. This means that the stock is trading at a premium of 2 times relative to the company's book value which reflects the total value of a company's assets that shareholders of that company would receive if the company were to be liquidated.
- The company's price-to-sales ratio, which shows how much the market values every dollar of the company's sales, currently stands at -770.94.
- The company's enterprise value-to-revenue multiple, which is often used to determine a company's valuation in the case of a potential acquisition, currently stands at -330.89.
P/E
-49.36
EBITDA
$-27,870,489
P/Book
1.86
Mkt Cap
$1B
P/Sales
-770.94
Revenue
$-163,971
EPS (TTM)
-0.16
PEG Ratio
0.03
EV/Revenue
-330.89
Total Cash
$72M
Debt/Equity
1.28
Forward P/E
0.00
Current Debt
$7M
Gross Profit
$-218,571
Dividend Date
-
Earnings Date
2022-09-27
Profit Margin
162.31
Revenue/Share
-0.00
Total Revenue
$-163,971
Enterprise Val
$54M
Put/Call Ratio
0.00
Revenue/Employee
0.00
Market Comparative Performance
- The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis
- The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis
- The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis
| Name | DoD %Δ | YTD %Δ | 1 Yr % | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|
| Palatin Technologies Inc. | 18.3 | -37.8 | -30.2 | -72.1 | 67.3 |
| Dow Jones Industrial Average | -0.5 | -13.6 | -9.4 | -16.2 | 3.5 |
| S&P 500 Index | -0.8 | -17.3 | -11.7 | -19.4 | 6.1 |
| Health Care | -0.4 | -10.9 | -6.4 | -11.9 | 7.3 |
Peer Group Comparative Performance
- The company's stock price performance year-to-date lags the peer average by 234.3%
- The company's stock price performance over the past 12 months lags the peer average by 140.9%
| Name | MKT CAP (USD) | P/E | YTD %Δ | 1 Yr %Δ | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|---|
| Palatin Technologies Inc. | PTN | -49.4 | -37.8 | -30.2 | -72.1 | 67.3 |
| Peer Avg | N/A | 64.5 | -11.3 | -12.5 | -34.0 | 46.7 |
| Johnson & Johnson | JNJ | 24.0 | -0.1 | 4.1 | -10.3 | 8.2 |
| Astrazeneca plc - ADR | AZN | -143.7 | 2.0 | 5.0 | -17.9 | 11.5 |
| Neurocrine Biosciences, Inc. | NBIX | 831.7 | 24.6 | 10.8 | -2.4 | 48.4 |
| Ligand Pharmaceuticals, Inc. - Class B | LGND | -186.0 | -43.1 | -34.9 | -47.7 | 22.5 |
| ANI Pharmaceuticals Inc | ANIP | -9.7 | -22.3 | 27.9 | -40.4 | 61.0 |
| Ardelyx Inc | ARDX | 0 | 19.1 | -2.2 | -28.1 | 181.5 |
| Medicinova Inc | MNOV | 0 | -14.6 | -41.3 | -52.5 | 6.2 |
| GlycoMimetics Inc | GLYC | 0 | -56.0 | -69.7 | -72.7 | 34.0 |
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.
Was this content valuable for you?
Tags: